ClinicalTrials.gg
CompletedNCT03765294Updated Dec 19, 2019

A Study to Investigate the Effects of ACT-541468 on Nighttime Respiratory Function in Patients With Mild to Moderate Obstructive Sleep Apnea

A Phase 1 interventional study of ACT-541468 and Placebo in Obstructive Sleep Apnea, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-19.

Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2019, 7 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 68 studies in Sleep Apnea, Obstructive with a site in Germany — 7 open to participants now, 13 under way, 5 of them phase 3. Sleep Apnea, Obstructive · Germany.

Enrollment
40th of 55
28 · median 80
Started
2019
with 5 others
Phase 1
2 of 68
none open now
Registered
46th of 68
by date

Among the 68 studies in Sleep Apnea, Obstructive with a site in Germany, this one is the 40th largest by enrollment of the 55 interventional ones that give a count, is one of 6 that started in 2019, is one of 2 in phase 1, and was the 46th registered.

Sleep Apnea, Obstructive

2,243 studies on the registry are indexed under Sleep Apnea, Obstructive; 475 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

7 of the 68 studies in Sleep Apnea, Obstructive with a site in Germany are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 313 Sleep Apnea, Obstructive studies recruiting now, 146 (47%) set no upper age limit and 124 (40%) stop at 75 or younger; 52 take children under 18; 65 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies in Sleep Apnea, Obstructive with a site in Germany, or all of them as a file.
02

Study summary

This study is conducted to investigate the effects of ACT-541468 on nighttime respiratory function in patients with mild to moderate obstructive sleep apnea

03

Conditions studied

  • Obstructive Sleep Apnea
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed in a language understandable to the subject prior to any study-mandated procedure.
  • Male and female subjects aged ≥ 18 years at Screening.
  • Women of must have a negative serum pregnancy test at Screening and a negative urine pregnancy test at Screening Visit 2 and on Day 1 pre-dose of the first period. They must agree to consistently and correctly use a highly effective method of with a failure rate of \< 1% per year.
  • Women of non-childbearing potential, i.e., , with previous bilateral salpingectomy, bilateral salpingo-oophorectomy or hysterectomy, or with premature ovarian failure, XY genotype, Turner syndrome, and/or uterine agenesis.
  • Diagnosis of OSA according to the International Classification of Sleep Disorders documented by medical history and confirmed in a sleep laboratory in the context of diagnosing OSA within the last 3 years.
  • Patient with mild to moderate intensity of OSA determined during OSA diagnosis and confirmed on the screening night PSG and defined as apnea/hypopnea index (AHI) ranging from 5 to \< 30.

Exclusion criteria

Exclusion Criteria:

  • Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.
  • Pregnant or lactating women.
  • Modified Swiss Narcolepsy Scale total score \< 0 at Screening, or history of narcolepsy or cataplexy.
  • Subjects with abnormality on the screening night PSG as per investigator judgment, including evidence of severe insomnia (i.e., sleep time \< 5 h) periodic limb movement disorder with arousal index ≥ 10/h, restless legs syndrome, circadian rhythm disorder, REM behavior disorder, parasomnia including nightmare disorder, sleep terror disorder, and/or sleepwalking disorder.
  • Need for continuous positive airway pressure device or a dental appliance device within the preceding 7 days prior to Screening Visit 2 and during the course of the study, i.e., from Screening Visit 2 to EOS.
  • Evidence of any other clinically significant active pulmonary disease such as (COPD) (as per Global Initiative for Obstructive Lung Disease), based on investigator's judgment.
  • History of surgical intervention for obstructive sleep apnea, except nose surgery.
  • SaO2 \< 90% during wakefulness or mean non-apneic SaO2 (i.e., outside events of apnea/hypopnea) \< 85% for > 5 consecutive min during the screening night PSG.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Treatment A: ACT-541468

    50 mg once daily from Day 1 to Day 5 of Period A

    Drug: ACT-541468

  • Placebo comparator
    Treatment B: Placebo

    Matching placebo once daily from Day 1 to Day 5 of Period B

    Drug: Placebo

Interventions

  • Film-coated tablet for oral use

  • DrugPlacebo

    Film-coated tablet for oral use

06

What researchers measure

Primary outcomes

  1. Apnea/hypopnea index (AHI) after multiple-dose administration of ACT-541468 as measured by polysomnography (PSG)

    AHI is defined by total number of apnea (pause in respiration ≥ 10 s) plus hypopnea (reduction in airflow or tidal volume from pre-event baseline by 30% for at least 10 s accompanied by a decrease of SaO2 ≥ 4%) events, divided by total sleep time (TST, in min), then multiplied by 60, during TST

    Time frame: After multiple-dose administration (i.e., at Night 5) (duration: 8 hours PSG recording)

Other outcomes

  1. AHI during TST after single-dose administration

    Time frame: After single-dose (i.e., Night 1) administration (duration: 8 hours PSG recording)

  2. Mean SaO2 during TST

    Time frame: After single-dose (i.e., Night 1) administration (duration: 8 hours PSG recording)

  3. AHI during the awake, non-REM, and REM phases

    Time frame: After single-dose (i.e., Night 1) administration (duration: 8 hours PSG recording)

  4. Mean SaO2 during the awake, non-REM, and REM phases

    Time frame: After single-dose (i.e., Night 1) administration (duration: 8 hours PSG recording)

  5. Percentage of TST during which SaO2 is < 90%, < 85%, and < 80%

    Time frame: After single-dose (i.e., Night 1) administration (duration: 8 hours PSG recording)

  6. Change from baseline to EOP of both periods in subjective next-day performance (morning sleepiness, daytime alertness, and daytime ability to function) as assessed by VAS

    Time frame: After single-dose (i.e., Night 1) and multiple-dose (i.e., Night 5) administration (duration: 2 x 8 hours PSG recording)

  7. Objective sleep parameters LPS, WASO, TST, and SEI following single- and multiple-dose administration, as measured by PSG

    Time frame: After single-dose (i.e., Night 1) and multiple-dose (i.e., Night 5) administration (duration: 2 x 8 hours PSG recording)

  8. Safety profile including incidence of adverse events (AEs) and serious adverse events (SAEs)

    Time frame: From baseline to EOS (duration: for up to 10 weeks)

07

Study locations

1 site
  • Advanced Sleep Research
    Berlin, 10117, Germany
08

References and documents

Publications

  • Boof ML, Ufer M, Fietze I, Pepin JL, Guern AS, Lemoine V, Dingemanse J. Assessment of the effect of the dual orexin receptor antagonist daridorexant on various indices of disease severity in patients with mild to moderate obstructive sleep apnea. Sleep Med. 2022 Apr;92:4-11. doi: 10.1016/j.sleep.2021.11.015. Epub 2022 Feb 12. PubMed 35306405 ↗
  • Boof ML, Dingemanse J, Lederer K, Fietze I, Ufer M. Effect of the new dual orexin receptor antagonist daridorexant on nighttime respiratory function and sleep in patients with mild and moderate obstructive sleep apnea. Sleep. 2021 Jun 11;44(6):zsaa275. doi: 10.1093/sleep/zsaa275. PubMed 33305817 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Nov 2019, 7 months.

Of 27 phase 1 interventional studies under Sleep Apnea, Obstructive, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 44. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2018
First posted
Dec 5, 2018
StartActual
Mar 14, 2019
Primary completionActual
Nov 5, 2019
CompletionActual
Nov 5, 2019
Last update
Dec 19, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03765294
Responsible party
Sponsor
First posted
Dec 5, 2018
Start date
Mar 14, 2019
Primary completion
Nov 5, 2019
Completion
Nov 5, 2019
Last update
Dec 19, 2019

Study contacts

Clinical Trials
study director · Idorsia Pharmaceuticals Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Daridorexant

Start the discussion